MedTrace Logo

Near Normalisation of BG Improves the Potentiating Effect of GLP-1

NCT00612625 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2008-02-12

No results posted yet for this study

Summary

The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

glucagon-like peptide-1

continuous infusion of GLP-1 (1½ pmol/kg/min)

DRUG

Saline

continuous infusion of saline

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Patricia V Højberg, MD, PHD · University Hospital Hvidovre

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2004-07-31
Completion
2004-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612625 on ClinicalTrials.gov